Mazdutide

also known as: IBI362, LY3305677, OXM-3

A weekly GLP-1/glucagon dual agonist approved in China for obesity (2025); the first OXM-mimetic to reach market.

An oxyntomodulin analog with balanced GLP-1 and glucagon receptor agonism, engineered for weekly dosing and approved in China for chronic weight management.

Mechanism of action

Oxyntomodulin-based dual agonism at GLP-1 and glucagon receptors. GLP-1 drives appetite suppression and glycemic control; glucagon contributes to energy expenditure and hepatic fat reduction. GLORY-1 Phase 3 trial in Chinese obese adults showed ~14.4% weight loss at 48 weeks with 9 mg weekly dosing.

Primary uses

Chronic weight management (China-approved)
Type 2 diabetes (Phase 3 China)
MASH (Phase 2)

Typical dosing

3–9 mg weekly (subcutaneous)

GLORY-1 trial titrated to 6 mg or 9 mg weekly. China labeling reflects Phase 3 regimen.

Regulatory status

Approved by China NMPA (June 2025) for chronic weight management. Developed by Innovent Biologics (licensed from Eli Lilly). Not FDA-approved; no active US trials at time of writing.

References

[clinical-trial] Ji L, et al. "Mazdutide for the treatment of obesity in Chinese adults (GLORY-1): a randomized, double-blind, placebo-controlled phase 3 trial." Lancet Diabetes Endocrinol, 2025.
[manufacturer] Innovent Biologics — Mazdutide (Xinerlai) China NMPA approval announcement, June 2025.
[clinical-trial] ClinicalTrials.gov NCT05657574 (GLORY-1, Phase 3).

Related peptides

Survodutide

A once-weekly GLP-1/glucagon co-agonist in late-stage trials for obesity, type 2 diabetes, and MASH.

Retatrutide

An investigational triple hormone agonist that produced ~24% weight loss at 48 weeks in Phase 2 — the largest in any single-agent obesity trial to date.

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.